Please try another search
WPD Pharmaceuticals Inc., a biotechnology research and development company, engages in the research and development of medicinal products in the fields of oncology. The company develops WPD101 to treat brain cancers; WPD102 for the treatment of uveal melanoma; Berubicin to treat glioblastoma multiforme; and WP1066 for the treatment of glioblastoma and melanoma brain metastases. It also develops WP1220 for the treatment of cutaneous T-cell lymphoma; WPD103, a radiopharmaceutical based on the expression of tumor-specific receptors, such as IL-13RA2 and EphA2; and Annamycin to treat solid tumors metastasis, breast, ovarian, lung, and lower gastrointestinal tract cancers. WPD Pharmaceuticals Inc. is headquartered in Vancouver, Canada.
Name | Age | Since | Title |
---|---|---|---|
Nicholas Luksha | 41 | 2023 | Director |
Teresa Liliana Rzepczyk | - | 2019 | Independent Director |
Romuald Apollo Harwas | - | 2022 | Director |
Waldemar Debinski | - | 2020 | Member of Scientific Advisory Board |
Constantine Carmichel | - | 2023 | Director |
Peter Novak | - | 2019 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review